Date Filed | Type | Description |
10/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
10/03/2023 |
4
| Tosca Melissa (EVP Finance) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 30,000 shares
@ $0 Granted 60,000 options to buy
@ $0.5677, valued at
$34.1k
|
|
10/03/2023 |
4
| Daniels Eric Joseph (Chief Development Officer) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 62,500 shares
@ $0 Granted 125,000 options to buy
@ $0.5677, valued at
$71k
|
|
10/03/2023 |
4
| Strem Brian M. (President and CEO) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 75,000 shares
@ $0 Granted 150,000 options to buy
@ $0.5677, valued at
$85.2k
|
|
10/03/2023 |
4
| TYLE PRAVEEN (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 5,000 options to buy
@ $0.5677, valued at
$2.8k
|
|
10/03/2023 |
4
| Shapiro Aron (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 5,000 options to buy
@ $0.5677, valued at
$2.8k
|
|
10/03/2023 |
4
| Stengone Carmine N. (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 8,000 options to buy
@ $0.5677, valued at
$4.5k
|
|
10/03/2023 |
4
| Hollander David (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted options to buy
@ $0.5677, valued at
$0 |
|
10/03/2023 |
4
| Gayron Kenneth L (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 5,000 options to buy
@ $0.5677, valued at
$2.8k
|
|
10/03/2023 |
4
| Parsons Erin (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 5,000 options to buy
@ $0.5677, valued at
$2.8k
|
|
09/27/2023 |
8-K
| Quarterly results |
08/10/2023 |
3
| Stengone Carmine N. (Director) has filed a Form 3 on KIORA PHARMACEUTICALS INC |
08/08/2023 |
8-K
| Quarterly results |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/01/2023 |
8-K
| Quarterly results |
07/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
07/20/2023 |
8-K
| Quarterly results |
07/11/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
06/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs:
|
"1,447,628 SHARES OF COMMON STOCK, 3,908 SHARES OF SERIES F CONVERTIBLE PREFERRED STOCK",
"KIORA PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS",
"KIORA PHARMACEUTICALS, INC. and VSTOCK TRANSFER, LLC, as Warrant Agent",
"Kiora Pharmaceuticals Announces Closing of" |
|
06/02/2023 |
424B1
| Form 424B1 - Prospectus [Rule 424(b)(1)]: |
06/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/15/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
05/12/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
05/09/2023 |
8-K
| Quarterly results |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/05/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
04/27/2023 |
8-K
| Quarterly results |
03/30/2023 |
8-K
| Quarterly results |
03/23/2023 |
8-K
| Quarterly results |
03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/07/2023 |
4
| Parsons Erin (Director) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 8,000 options to buy
@ $3.83, valued at
$30.6k
|
|
03/07/2023 |
4
| Tosca Melissa (EVP Finance) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 2,400 shares
@ $0 Granted 1,600 options to buy
@ $3.83, valued at
$6.1k
|
|
03/07/2023 |
4
| Strem Brian M. (President and CEO) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 15,600 shares
@ $3.83, valued at
$59.7k
Granted 10,400 options to buy
@ $3.83, valued at
$39.8k
|
|
03/07/2023 |
4
| Daniels Eric Joseph (Chief Development Officer) has filed a Form 4 on KIORA PHARMACEUTICALS INC
Txns:
| Granted 15,600 shares
@ $0 Granted 10,400 options to buy
@ $3.83, valued at
$39.8k
|
|
|